ABSTRACT -We previously demonstrated that 28-day administration of carcinogens that evoked cell proliferation as determined by immunoreactivity for Ki-67 or minichromosome maintenance 3 (Mcm3), in many target organs, increased the numbers of topoisomerase (Topo) IIα + , ubiquitin D (Ubd) + , and TUNEL + apoptotic cells. We also found increased co-expression of Topo IIα and Ubd, suggestive of increased spindle checkpoint disruption at the M phase. To investigate the roles of these markers in the early stages of carcinogenesis, we examined distribution changes in several carcinogenic target organs using rat initiation-promotion models. Promoting agents targeting the liver (piperonyl butoxide, methapyrilene hydrochloride), thyroid (sulfadimethoxine), urinary bladder (phenylethyl isothiocyanate), and forestomach and glandular stomach (catechol) were administered to rats after initiation treatment for each target organ. Numbers of Ki-67 + , Mcm3 + , Topo IIα + and TUNEL + cells increased within preneoplastic lesions as determined by glutathione S-transferase placental form in the liver or phospho-p44/42 mitogen-activated protein kinase in the thyroid, and hyperplastic lesions having no known preneoplastic markers in the urinary bladder, forestomach and glandular stomach. On the other hand, Ubd + cells did not increase within these preneoplastic lesions, but increased within hyperplastic lesions. These results suggest that both cell proliferation and apoptosis may be involved in the formation of preneoplastic lesions in the liver and thyroid examined here; however, spindle checkpoint disruption may not be involved in this process. Changes in hyperplastic lesions of the urinary bladder, forestomach and glandular stomach are similar to the 28-day carcinogen-treated cases, suggestive of the hyperplastic cellular character before the preneoplastic state.
INTRODUCTION
There is no reliable rapid means of evaluating the carcinogenic potential of chemicals. Carcinogenic bioassays are typically time-consuming and expensive 1.5-or 2-year studies using mice or rats. Alternative animal models using gene engineering technologies (Eastin, 1998) or two-stage carcinogenesis models (Tamano, 2010) are also expensive and time-consuming or have limited target organs. Toxicogenomic approaches for prediction of carcinogenic potential in target organs appear promising; however, they are also expensive and require some integrative methodologies between different laboratories sharing an expression database (Jonker et al., 2009; Uehara et al., 2011) .
In rodent studies, nuclear enlargement is sometimes found from the early stages in target cells after repeated administration of carcinogens, irrespective of their genotoxic potential (Adler et al., 2009 ). This nuclear change is typically observed in the kidney, and is referred to as karyomegaly. Recent studies have shown that ochratoxin A, a renal carcinogen that typically induces karyomegaly, induces aberrant expression of cell cycle-related molecules in proximal tubular areas with karyomegaly (Adler Fluctuations in cell proliferation, apoptosis, and cell cycle regulation at the early stage of tumor promotion in rat two-stage carcinogenesis models et al., 2009) . It is suggested that this aberrant expression may eventually cause carcinogenicity associated with chromosomal instability. We therefore hypothesize that an early event that disrupts regulation of the cell cycle triggers the carcinogenic response in the molecular mechanism responsible for the development of karyomegaly. We previously analyzed cell cycle-related molecules after 28 days of repeated administration of renal carcinogens that do or do not induce karyomegaly in rats (Taniai et al., 2012a) . We found that renal carcinogens, irrespective of their karyomegaly-inducing potential, increased the numbers of proximal tubular cells positive for Ki-67, a cell proliferation marker, and topoisomerase (Topo) IIα, suggesting that cell proliferation is accompanied by cell cycle aberrations. Next, we analyzed other cellular markers against renal carcinogens selected based on microarray analysis, and extended our search to marker molecules for prediction of carcinogenicity in other target organs such as the liver, thyroid, urinary bladder, forestomach, glandular stomach, and colon in a 28-day treatment scheme. Obtained results suggested that aberrant expression of ubiquitin D (Ubd) at G 2 phase and increased apoptosis reflecting aberrant cell cycle regulation may be the common feature of carcinogens that show high proliferative activity after a 28-day treatment in many target organs (Taniai et al., 2012b) . However, some carcinogens that did not induce cell proliferation in the target organ, such as piperonyl butoxide (PBO) in the liver and colonic carcinogens, did not increase the number of Topo IIα + or Ubd + cells or apoptosis. The present study aimed to clarify the involvement of cell proliferation, apoptosis, and cell cycle function of Topo IIα and Ubd in the early carcinogenic processes of formation of hyperplastic or preneoplastic lesions. For this purpose, we examined the immunohistochemical cellular distributions of related molecules and TUNEL + apoptotic cells at the early stages of tumor promotion in the liver, thyroid, urinary bladder, forestomach, and glandular stomach using two-stage carcinogenesis models.
MATERIALS AND METHODS

Chemicals
Methapyrilene hydrochloride (MP; , N-diethylnitrosamine (DEN; CAS No. 55-18-5, > 99.0%) and sulfadimethoxine sodium salt (SDM; CAS No. 122-11-2) were purchased from Sigma-Aldrich Japan K. K. (Tokyo, Japan). 1-Methyl-3-nitro-1-nitrosoguanidine (MNNG; > 95.0%), nitrosamine (BBN; CAS No. 3817-11-6, > 90.0%) and phenylethyl isothiocyanate (PEITC; CAS No. 2257-09-2, ≥ 97.0%) were obtained from Tokyo Fig. 1 . Experimental design. Vol. 37 No. 6 Chemical Industry Co. (Tokyo, Japan). Catechol , > 99.0%) was purchased from Wako Pure Chemicals Industries (Osaka, Japan). N-bis(2-hydroxypropyl)nitrosamine (DHPN; CAS No. 53609-64-6) was purchased from Nacalai Tesque (Kyoto, Japan). Piperonyl butoxide (PBO; CAS No. 51-03-6, 90%) was obtained from Nagase & Co. (Osaka, Japan).
Animal experiments
Five-week-old male F344/NSlc rats were purchased from Japan SLC, Inc. (Shizuoka, Japan) and acclimatized to a powdered basal diet (Oriental Yeast Co., Tokyo, Japan) and tap water ad libitum. They were housed in stainless steel cages in a barrier-maintained animal room on a 12 hr light-dark cycle at 23 ± 3°C with a relative humidity of 50 ± 20%.
After a one-week acclimatization period, animals were subjected to two-stage carcinogenesis bioassays as described in Fig. 1 . To study the liver as the target organ, medium-term liver bioassay was employed (Shirai, 1997) . All animals were initiated with a single intraperitoneal injection of DEN (200 mg/kg body weight). Two weeks later, animals were divided into three groups and were fed the basal diet (DEN-alone) or a diet containing either PBO at 20,000 ppm (DEN + PBO) or MP at 1,000 ppm (DEN + MP) for 6 weeks. The animals were subjected to a two-thirds partial hepatectomy at week 3. The selected dose of PBO and MP has shown to promote induction of preneoplastic lesions as determined by glutathione S-transferase placental form (GST-P) in the liver after 6-week administration in a two-stage model (Horn et al., 1996; Ichimura et al., 2010) . To study the thyroid as the target organ, all animals were initiated with a single subcutaneous injection of DHPN (2,800 mg/kg body weight). One week later, animals were given drinking water with (DHPN + SDM) or without (DHPN-alone) SDM at 1,500 ppm for 4 weeks. The selected dose of SDM has shown to promote induction of follicular cell carcinomas after 13-week administration in a two-stage model (Kemmochi et al., 2012) . To study the urinary bladder as the target organ, all animals were initiated with BBN at 500 ppm in the drinking water for 4 weeks. Animals were then given either the basal diet (BBN-alone) or a diet containing PEITC at 1,000 ppm (BBN + PEITC) for 8 weeks. The selected dose of PEITC has shown to promote induction of transitional cell carcinomas for 32-week administration in a two-stage model . To study the forestomach and glandular stomach, all animals were initiated with a single gavage of MNNG (150 mg/kg body weight). One week later, animals were either fed the basal diet (MNNG-alone) or a diet containing catechol at 8,000 ppm (MNNG + Catechol) for 12 weeks. The selected dose of catechol has shown to promote induction of both forestomach and glandular stomach carcinomas after 51-week administration in a two-stage model (Wada et al., 1998) . After cessation of tumor-promotion, all animals were killed by exsanguination from the abdominal aorta under deep anesthesia and target organs were removed.
All target organs were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer solution (pH 7.4; Wako Pure Chemicals Industries, Ltd.). At autopsy, the urinary bladder was inflated by transurethral instillation of paraformaldehyde solution, and the stomach was instilled with paraformaldehyde solution to facilitate mucosal fixation. The following samples were taken from fixed tissues and prepared for paraffin embedding: one slice each from the median and left lobes of the liver; bilateral lobes of the thyroid; two longitudinal slices of the urinary bladder; and three longitudinal slices of the stomach including the forestomach and glandular stomach.
All procedures in this study were conducted in compliance with the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan, June 1, 2006) and according to the protocol approved by the Animal Care and Use Committee of the Tokyo University of Agriculture and Technology.
Histopathology, immunohistochemistry, and apoptosis assay
Of the paraffin-embedded tissues from the liver, thyroid, urinary bladder, and stomach (forestomach and glandular stomach), 3 μm sections were stained with hematoxylin and eosin for histopathological examination and subjected to immunohistochemistry.
Immunohistochemistry was performed using the Vectastain ® Elite ABC Kit (Vector Laboratories Inc., Burlingame, CA, USA) with 3, 3'-diaminobenzidine/H 2 O 2 as the chromogen. The following primary antibodies were used: (Scholzen and Gerdes, 2000) . Mcm3, a molecule involved in DNA replication, is suggested to be a proliferation marker similar to Ki-67 . Topo IIα unlinks DNA catenation from the late S to the G 2 /M phases (Goswami et al., 1996; Bower et al., 2010) . Ubd leads to chromosomal instability through reduction of kinetochore localization of checkpoint proteins, such as Mad2, during G 2 /M phase (Lim et al., 2006; Herrmann et al., 2007) .
To detect preneoplastic lesions in the liver and thyroid, the following antibodies were used: GST-P rabbit polyclonal antibody (1: 1,000; Catalog No. 311, Medical & Biological Laboratories Co., Ltd., Nagoya, Japan) and phospho-p44/42 mitogen-activated protein kinase (Thr202/Tyr204) (p-Erk1/2; 1:400; Catalog No. 4370, Cell Signaling Technology, Inc.).
Antigen retrieval was carried out in an autoclave for 10 min at 121°C in 10 mM citrate buffer (pH 6.0) for all antibodies except for GST-P. Sections were counterstained with hematoxylin for microscopic examination.
To examine the apoptotic cell index, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-assay was performed using the ApopTag ® Peroxidase In Situ Apoptosis Detection Kit (Millipore, Billerica, MA, USA) according to the manufacturer's protocol. Briefly, deparaffinized sections were treated with 20 μg/ml proteinase K for 15 min at room temperature. Endogenous peroxidase activity was blocked with 3.0% hydrogen peroxide. Color development and counter staining were as described above for immunohistochemistry.
Analysis of immunoreactivity
For the liver, the number and areas of GST-P + liver cell foci larger than 0.2 mm in diameter, and the total areas of the liver sections were measured as described previously . For the thyroid, the number and areas of p-Erk1/2 + focal follicular cell hyperplasias (FFCHs) consisting of ≥ 4 cells, and the total areas of the thyroid sections were measured. The numbers of Ki-67 + , Mcm3 + , Topo IIα + , Ubd + and TUNEL + cells were counted in 10 randomly selected GST-P + foci or p-Erk1/2 + FFCHs at a magnification of 400 ×, and the ratio of positive cells to the total liver or thyroid follicular cells counted was calculated for both the inside and outside regions of the GST-P + foci or p-Erk1/2 + FFCHs. For this purpose, liver cell foci of ≥ 0.2 mm in diameter and FFCHs consisting of ≥ 200 cells were selected. The percentage of positive cells was determined in each field. The numbers of immunoreactive cells and TUNEL + cells in the outside regions of the GST-P + foci or p-Erk1/2 + FFCHs were also similarly counted in initiation-alone groups. For the urinary bladder, the numbers of Ki-67 + , Mcm3 + , Topo IIα + , Ubd + and TUNEL + cells were counted in 5 randomly selected areas of the urothelium in the BBN-alone group, 5 each of simple hyperplasias, papillary and nodular (PN) hyperplasias and surrounding areas in the BBN + PEITC group at a magnification of 400 ×, and normalized with the unit length of muscularis mucosae in each field. For the forestomach, the numbers of Ki-67 + , Mcm3 + , Topo IIα + , Ubd + and TUNEL + cells were counted in 10 randomly selected areas of the mucosa in the MNNG-alone group, 10 each of hyperplasias and surrounding areas in the MNNG + Catechol group at a magnification of 400 ×. The number of positive cells was normalized with the unit length of muscularis mucosae in each field. For the glandular stomach, the numbers of Ki-67 + , Mcm3 + , Topo IIα + , Ubd + and TUNEL + cells were counted in 5 randomly selected areas of the pyloric gland epithelia except for proliferative zones in the MNNG-alone group, 5 each of small hyperplastic foci consisting of 4-10 irregularshaped tubules accompanied with increased cellular density, large hyperplastic foci consisting of glandular epithelial cells often showing goblet cell differentiation, and surrounding tubular epithelia except for proliferative zones in the MNNG + Catechol group at a magnification of 400 ×. The ratio of positive cells was estimated as the percentage of the total number of cells in the hyperplastic foci or each field.
Statistical analysis
For comparison of the numerical data between multiple groups, Bartlett's test for equal variance was used to determine whether the variance was homogenous between the groups. If a significant difference in variance was not observed, a one-way analysis of variance was carried out. If significant differences were found, Tukey's test was performed for comparison between the groups. If a significant difference using Bartlett's test was observed, SteelDwass' test was performed.
Comparisons between two groups, i.e., the number and area of p-Erk1/2 + FFCHs of the thyroid between the DHPN-alone and DHPN + SDM groups, were analyzed with Student's t-test when the variance was proven to be homogenous among the groups, using a test for equal variance. If a significant difference in variance was observed, the Welch's t-test was performed.
RESULTS
Tumor-promoting activity in the liver and thyroid
After 6 weeks of tumor promotion with PBO or MP, both the number and area of GST-P + liver cell foci, which have been confirmed as preneoplastic lesions of liver cells (Shirai, 1997; Ito et al., 2000) , were significantly increased compared with the DEN-alone group (Table 1) . In case of FFCHs, which are considered to be early pre-neoplastic lesions (Shima et al., 2009; Ago et al., 2010) , we found positive immunoreactivity for p-Erk1/2. When p-Erk1/2 + FFCHs were measured after 4 weeks of tumor promotion with SDM, both the number and area of these lesions were significantly increased as compared with the DHPN-alone group (Table 2) .
Marker distributions in early hepatocarcinogenesis
Ki-67 + , Mcm3 + , Topo IIα + , Ubd + , and TUNEL + liver cells were sparsely distributed within the liver lobules in the DEN-alone animals. In the PBO and MP-promoted groups, GST-P + foci in the liver showed greater numbers of cells immunoreactive for Ki-67, Mcm3 or Topo IIα, and of TUNEL + cells than the outside of the GST-P + foci (Figs. 2A-C, E). There were no obvious differences in the number of Ubd + liver cells between the areas inside and outside of the GST-P + foci in the PBO or MP-promoted group (Fig. 2D ).
There were no obvious differences in the numbers of Ki-67 + , Mcm3 + , Topo IIα + , Ubd + and TUNEL + liver cells distributed outside of the GST-P + foci between the DENalone group and PBO-promoted group ( Figs. 2A-E) . On the other hand, the numbers of Ki-67 + , Mcm3 + , and Topo IIα + cells distributed outside of the GST-P + foci in the MP-promotion group were higher than those in the DENalone group (Figs. 2A-C ). There were no obvious differences in the number of Ubd + and TUNEL + liver cells distributed outside of the GST-P + foci between the MPpromoted group as compared with the DEN-alone group (Figs. 2D and E).
Marker distributions in early thyroid carcinogenesis
Ki-67 + , Mcm3 + , Topo IIα + , Ubd + , and TUNEL + follicular cells were sparsely distributed in the thyroids of the DHPN-alone animals. In the SDM-promoted group, the p-Erk1/2 + FFCHs showed greater number of follicular cells immunoreactive for Ki-67, Mcm3 and Topo IIα than the outside of the p-Erk1/2 + FFCHs (Figs.  3A-C ). There were no obvious difference in the number of Ubd + follicular cells between the inside and outside of the p-Erk1/2 + FFCHs in the SDM-promoted group (Fig. 3D) . Though statistically non-significant, the p-Erk1/2 + FFCHs showed greater number of TUNEL + cells than the outside of the p-Erk1/2 + FFCHs (Fig. 3E) . The numbers of Ki-67 + , Mcm3 + , and Topo IIα + cells distributed outside of the p-Erk1/2 + FFCHs in the SDM-promoted group were higher than those in the DHPN-alone group (Figs. 3A-C). There were no obvious differences in the numbers of Ubd + and TUNEL + cells distributed outside of the p-Erk1/2 + FFCHs between the DHPN-alone and SDM-promoted groups (Figs. 3D and E) .
Marker distributions in early urinary bladder carcinogenesis
Tumor promotion with PEITC resulted in induction of simple hyperplasias and PN hyperplasias of the urothelium in the urinary bladder at week 8. Ki-67 + , Mcm3 + , Topo IIα + , Ubd + , and TUNEL + epithelial cells were sparse- ly distributed in the urothelium of the BBN-alone group. In the PEITC-promoted group, numbers of Ki-67 + , and Mcm3 + epithelial cells were significantly increased in the simple and PN hyperplasias and in the surrounding epithelial cells as compared with the urothelium of the BBNalone group (Figs. 4A and B) . The numbers of Topo IIα + and Ubd + epithelial cells were significantly increased in the simple and PN hyperplasias of the PEITC-promoted group as compared with the urothelium of the BBN-alone group (Figs. 4C and D) . The number of TUNEL + epithelial cells was significantly increased only in the PN hyperplasias of the PEITC-promoted group as compared with the urothelium of the BBN-alone group (Fig. 4E) . Within the PEITC-promoted group, the numbers of Ki-67 + , Mcm3 + and Topo IIα + epithelial cells were significantly increased in the simple hyperplasias and PN hyperplasias as compared with the surrounding epithelial cells. These immunoreactive cell populations were also significantly increased in the PN hyperplasias as compared with the simple hyperplasias. The numbers of Ubd + and TUNEL + cells were significantly increased in the PN hyperplasias as compared with the simple hyperplasias or surrounding epithelial cells.
Marker distributions in early forestomach carcinogenesis
Tumor promotion with catechol resulted in induction of hyperkeratosis/parakeratosis and hyperplasias of stratified epithelia in the forestomach at week 12. Ki-67 + , Mcm3 + , Topo IIα + , Ubd + , and TUNEL + mucosal epithelial cells were sparsely distributed in the mucosa of the MNNG-alone group. In the catechol-promoted group, numbers of Ki-67 + , Mcm3 + , Topo IIα + and Ubd + epithelial cells were significantly increased in the hyperplasias and surrounding epithelial cells as compared with the mucosa of the MNNG-alone group (Figs. 5A-D) . The number of TUNEL + epithelial cells was significantly increased in the hyperplasias of the catechol-promoted group as compared with the mucosa of the MNNG-alone group (Fig. 5E ). Within the catechol-promoted group, the numbers of Ki-67 + , Mcm3 + , Topo IIα + , Ubd + and TUNEL + epithelial cells were significantly increased in the hyperplasias as compared with the surrounding epithelial cells.
Marker distributions in early glandular stomach carcinogenesis
Tumor promotion with catechol resulted in induction of small and large hyperplastic foci in the glandular stomach at week 12. Ki-67 + , Mcm3 + , Topo IIα + , Ubd + , and TUNEL + glandular epithelial cells were sparsely distributed in the pyloric gland epithelia of the MNNGalone group. In the catechol-promoted group, the numbers of Ki-67 + and Mcm3 + glandular epithelial cells were significantly increased in the small and large hyperplastic foci as compared with the pyloric gland epithelia of the MNNG-alone group (Figs. 6A and B) . The numbers of Topo IIα + and Ubd + glandular epithelial cells were significantly increased in both the small and large hyperplastic foci and in the surrounding glandular epithelial cells of the catechol-promoted group as compared with the glandular epithelial cells of the MNNG-alone group (Figs. 6C and D) . The number of TUNEL + glandular epithelial cells was significantly increased only in small hyperplastic foci of the catechol-promoted group as compared with the glandular epithelial cells of the MNNGalone group (Fig. 6E) . Within the catechol-promoted group, the numbers of Ki-67 + , Mcm3 + and Topo IIα + glandular epithelial cells were significantly increased in both the small and large hyperplastic foci as compared with the surrounding glandular epithelial cells. These immunoreactive cell populations were significantly decreased in the large hyperplastic foci as compared with the small hyperplastic foci. The number of Ubd + glandular epithelial cells was significantly increased in the small hyperplastic foci as compared with the large hyperplastic foci or the surrounding glandular epithelial cells. The number of TUNEL + glandular epithelial cells was significantly increased in the small hyperplastic foci as compared with the surrounding glandular epithelial cells.
DISCUSSION
We previously demonstrated that carcinogens, irrespective of their target organs as well as karyomegalyinducing potential, increased the numbers of Ki-67 + and Mcm3 + cells, reflecting cell proliferation, Topo IIα + and Ubd + cells, and TUNEL + apoptotic cells after 28 days of administration, with the exception of the hepatocarcinogen PBO and colon carcinogens that do not induce proliferation activity (Taniai et al., 2012a (Taniai et al., , 2012b . In the present study, we examined these cellular populations at the early stages of tumor promotion targeting the liver, thyroid, urinary bladder, forestomach and glandular stomach. We found that the numbers of Ki-67 + , Mcm3 + , Topo IIα + and TUNEL + cells were significantly increased within the altered liver cell foci as determined by GST-P-immunoreactivity, FFCHs that were exclusively immunoreactive for p-Erk1/2 in the thyroid, PN hyperplasias in the urinary bladder, mucosal hyperplasias of the forestomach, and small hyperplastic foci of the glandular stomach as compared with the surrounding non-preneoplastic or nonhyperplastic cells, except for non-significant increase of apoptotic cells within FFCHs in the thyroid. The number of Ubd + cells increased within PN hyperplasias in the urinary bladder, mucosal hyperplasias of the forestomach, and small hyperplastic foci of the glandular stomach, but not within GST-P + liver cell foci or p-Erk1/2 + FFCHs, as compared with surrounding cells. It is generally accepted that preneoplastic lesions have high proliferation activity as compared with the surrounding non-neoplastic cells (Ogawa, 2009; Miyamoto et al., 2010) . We previously reported that high proliferation activity was attained within GST-P + liver cell foci and thyroid FFCHs at the early stages of tumor promotion (Shima et al., 2009; Tsuchiya et al., 2012) . Both types of lesion are well established as preneoplastic lesions that can develop into neoplastic lesions (Shirai, 1997; Ito et al., 2000; Shima et al., 2009; Ago et al., 2010) . In the present study, these preneoplastic lesions also showed high cell proliferation activity. In a previous study, we showed that all hepatocarcinogens studied, except for PBO, increased liver cell proliferation activity after 28 days of administration in rats (Taniai et al., 2012b) . We discussed a possible connection between the relatively weak tumor-promoting potential of PBO and the lack of proliferation activity after 28 days of treatment. However, in our present study we detected an apparent tumorpromoting activity of PBO that was similar to MP. Therefore we suggest that the high proliferation activity within GST-P + foci was attributable to the carcinogenic mechanism of this compound. The high proliferation activities in liver cells induced by other hepatocarcinogens after 28 days of administration in our previous study may be parallel to their hepatocarcinogenic potentials. However, it is not clear whether the induction of proliferation activity is directly linked to the carcinogenic mechanism (Taniai et al., 2012b) . Considering that weak carcinogens may require high doses and long exposure times to initiate the carcinogenic process after repeated administration, a 28-day treatment period may not be sufficient for induction of proliferation activity with PBO.
The balance between cell proliferation and apoptosis plays an important role in neoplastic tissue growth (Foster, 2000) . In the two-stage hepatocarcinogenesis model, tumor promotion treatment reduces apoptosis within preneoplastic GST-P + liver cell foci (Borbath et al., 2007) . However, in the present study we found that both PBO and MP-promoted livers increased both proliferation and apoptosis within GST-P + liver cell foci. Similar results have previously been shown after liver tumor-promotion with orotic acid in rats (Columbano et al., 1984) . We also detected increased apoptosis within SDM-promoted FFCHs, although this was statistically non-significant.
It has been reported that the populations of preneoplastic and neoplastic liver lesions expressing Bcl-2 or BclxL are different among non-genotoxic hepatocarcinogens (Christensen et al., 1999) . These differences may produce variations in the cellular signaling mechanism regulating apoptosis within these lesions among tumor-promoting agents. In experimental mammary carcinogenesis, both increased cell proliferation and apoptosis in hyperplastic glandular lesions causes increased cellular turnover, which contributes to tumor-progression (Arendt et al., 2006) . The promotion effect of PBO and MP involves generation of reactive oxygen species or membrane lipid peroxidation of liver cells (Perera et al., 1985; . In parallel with the apoptotic effect, enhanced oxidative stress in the liver and thyroid is involved in promotion from the early stages, which suggests that oxidative cellular stress may contribute to apoptosis (Woo et al., 2009; Mizukami et al., 2010) . These observations suggest that the number of apoptotic cells may increase or decrease within preneoplastic lesions depending on the tumor-promoting agent.
In the present study, tumor-promotion of the liver and thyroid increased the number of Topo IIα + cells within GST-P + foci and p-Erk1/2 + FFCHs, similar to cell proliferation activity. Topo IIα has been shown to be a reliable indicator of cell proliferation similar to Ki-67 (Hafian et al., 2004) . In our previous study, we demonstrated that renal carcinogens induced Topo IIα activation in parallel with high cell proliferation activity after 28 days of administration (Taniai et al., 2012a) . Because expression of Topo IIα covers wide range of cell cycle phases starting from the late S to the G 2 and M phase (Goswami et al., 1996; Bower et al., 2010) , the increase in Topo IIα + cells in GST-P + foci and p-Erk1/2 + FFCHs may indicate cell proliferation in the present study.
In addition to Topo IIα, upregulation of Ubd has been shown in preneoplastic lesions and carcinomas in mouse hepatocarcinogenesis models (Oliva et al., 2008; French et al., 2011) . However, in the present study, the number of Ubd + cells did not increase within preneoplastic lesions in the liver and thyroid. While the reason for this discrepancy in Ubd response is unclear, it is known that Ubd leads to chromosomal instability through reduction of kinetochore localization of spindle checkpoint proteins such as Mad2 (Lim et al., 2006; Herrmann et al., 2007) . We previously found co-expression of Topo IIα and Ubd after 28-day treatment with carcinogens evoking cell proliferation, which suggests induction of spindle checkpoint disruption at the M phase, presumably as an initial event to enter carcinogenic process (Taniai et al., 2012b) . Considering that we found no obvious differences in the number of Ubd + cells between inside and outside of preneoplastic lesions in the liver and thyroid, spindle checkpoint disruption at the M phase may not be involved in the cellular process of these preneoplastic lesions examined here.
In the present study, PN hyperplasias in the urinary bladder, mucosal hyperplasias of the forestomach and small hyperplastic foci of the glandular stomach all showed increased cellular distribution of Ubd as well as Ki-67, Mcm3, Topo IIα and apoptosis as compared with the surrounding cells. This was in contrast with the unchanged cellular distribution of Ubd in GST-P + liver cell foci and p-Erk1/2 + FFCHs. As we found similar cellular responses after 28-day treatment in our previous study (Taniai et al., 2012b) , spindle checkpoint disruption at the M phase may be the cellular process of tumor promotion in these target cells, in contrast with the promotion process in the liver and thyroid examined here. Considering no known preneoplastic markers, these hyperplastic lesions may not acquire preneoplastic cellular characters in contrast to the liver and thyroid preneoplastic lesions.
In conclusion, preneoplastic lesions identified with preneoplastic cellular markers in the liver and thyroid showed both increased cell proliferation and apoptosis. However, we found no specific expression of Ubd + cells in relation with these preneoplastic lesions. This was in contrast with the changes in Ubd expression in the liver and thyroid after 28 days of treatment in our previous study (Taniai et al., 2012b) . These results suggest that both cell proliferation and apoptosis may be involved in the formation of early preneoplastic lesions in the liver and thyroid. However, spindle checkpoint disruption at the M phase may not be involved in the cellular process of these preneoplastic lesions. We also observed increased Ubd + cell populations in hyperplastic lesions in the urinary bladder, forestomach and glandular stomach as compared with the surrounding cells, in conjunction with increases in cell proliferation, Topo IIα + and TUNEL + apoptotic cells. This was similar to the results from the 28-day treatment study targeting these organs reported previously (Taniai et al., 2012b) , suggestive of the hyperplastic cellular character of these lesions before entering to the preneoplastic state, different from preneoplastic lesions in the liver and thyroid.
